Latest development in viral vectors for gene therapy

被引：167

作者：

Lundstrom, K ^{[1
]}

机构：

[1] Regulon Inc BioXtal, CH-1066 Epalinges, Switzerland

来源：

TRENDS IN BIOTECHNOLOGY | 2003年 / 21卷 / 03期

关键词：

D O I：

10.1016/S0167-7799(02)00042-2

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Gene therapy includes the application of various viral vectors, which represent most types and families of viruses, suitable for infection of mammalian host cells. Both hereditary diseases and acquired illnesses, such as cancer, can be targeted. Because of the various properties of each viral vector, the definition of their application range depends on factors such as packaging capacity, host range, cell- or tissue-specific targeting, replication competency, genome integration and duration of transgene expression. Recent engineering of modified viral vectors has contributed to improved gene delivery efficacy.

引用

收藏

页码：117 / 122

页数：6

相关论文

共 44 条

[1]

Akkaraju GR, 1999, J GENE MED, V1, P280, DOI 10.1002/(SICI)1521-2254(199907/08)1:4<280::AID-JGM45>3.0.CO

[2]

2-L

[3] Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography [J].

Asselin-Paturel, C ;

Lassau, N ;

Guinebretière, JM ;

Zhang, J ;

Gay, F ;

Bex, F ;

Hallez, S ;

Leclere, J ;

Peronneau, P ;

Mami-Chouaib, F ;

Chouaib, S .

GENE THERAPY, 1999, 6 (04) :606-615

[4] Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye [J].

Auricchio, A ;

Rivera, VM ;

Clackson, T ;

O'Connor, EE ;

Maguire, AM ;

Tolentino, MJ ;

Bennett, J ;

Wilson, JM .

MOLECULAR THERAPY, 2002, 6 (02) :238-242

[5] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].

BLAESE, RM ;

CULVER, KW ;

MILLER, AD ;

CARTER, CS ;

FLEISHER, T ;

CLERICI, M ;

SHEARER, G ;

CHANG, L ;

CHIANG, YW ;

TOLSTOSHEV, P ;

GREENBLATT, JJ ;

ROSENBERG, SA ;

KLEIN, H ;

BERGER, M ;

MULLEN, CA ;

RAMSEY, WJ ;

MUUL, L ;

MORGAN, RA ;

ANDERSON, WF .

SCIENCE, 1995, 270 (5235) :475-480

[6] HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].

Bonini, C ;

Ferrari, G ;

Verzeletti, S ;

Servida, P ;

Zappone, E ;

Ruggieri, L ;

Ponzoni, M ;

Rossini, S ;

Mavilio, F ;

Traversari, C ;

Bordignon, C .

SCIENCE, 1997, 276 (5319) :1719-1724

[7] VESICULAR STOMATITIS-VIRUS G GLYCOPROTEIN PSEUDOTYPED RETROVIRAL VECTORS - CONCENTRATION TO VERY HIGH-TITER AND EFFICIENT GENE-TRANSFER INTO MAMMALIAN AND NONMAMMALIAN CELLS [J].

BURNS, JC ;

FRIEDMANN, T ;

DRIEVER, W ;

BURRASCANO, M ;

YEE, JK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (17) :8033-8037

[8] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J].

Cavazzana-Calvo, M ;

Hacein-Bey, S ;

Basile, CD ;

Gross, F ;

Yvon, E ;

Nusbaum, P ;

Selz, F ;

Hue, C ;

Certain, S ;

Casanova, JL ;

Bousso, P ;

Le Deist, F ;

Fischer, A .

SCIENCE, 2000, 288 (5466) :669-672

[9] Gene therapy: A tragic setback [J].

Check, E .

NATURE, 2002, 420 (6912) :116-118

[10] Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion [J].

Cheng, WF ;

Hung, CF ;

Hsu, KF ;

Chai, CY ;

He, LM ;

Polo, JM ;

Slater, LA ;

Ling, M ;

Wu, TC .

HUMAN GENE THERAPY, 2002, 13 (04) :553-568

← 1 2 3 4 5 →